Skip to main content

FDA Approvals

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma

Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease

Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma

FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor

Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia

Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

Page 9 of 53
Results 81 - 90 of 522